Insmed Incorporated

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Insmed Incorporated 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About INSM

Insmed, Inc. is a global biopharmaceutical company, which engages in the development and commercialization of therapies for patients with rare diseases. Its focuses on Brensocatib, and Treprostinil Palmitil Inhalation Powder (TPIP) pipeline. 

CEO
William H. Lewis
CEOWilliam H. Lewis
Employees
1,664
Employees1,664
Headquarters
Bridgewater, New Jersey
HeadquartersBridgewater, New Jersey
Founded
1988
Founded1988
Employees
1,664
Employees1,664

INSM Key Statistics

Market cap
24.59B
Market cap24.59B
Price-Earnings ratio
-39.98
Price-Earnings ratio-39.98
Dividend yield
—
Dividend yield—
Average volume
4.26M
Average volume4.26M
High today
$116.37
High today$116.37
Low today
$110.01
Low today$110.01
Open price
$113.60
Open price$113.60
Volume
5.18M
Volume5.18M
52 Week high
$212.75
52 Week high$212.75
52 Week low
$90.39
52 Week low$90.39

Stock Snapshot

With a market cap of 24.59B, Insmed Incorporated(INSM) trades at $114.00. The stock has a price-to-earnings ratio of -39.98.

During the trading session on 2026-11-02, Insmed Incorporated(INSM) shares reached a daily high of $116.37 and a low of $110.01. At a current price of $114.00, the stock is +3.6% higher than the low and still -2.0% under the high.

Trading volume for Insmed Incorporated(INSM) stock has reached 5.18M, versus its average volume of 4.26M.

The stock's 52-week range extends from a low of $90.39 to a high of $212.75.

The stock's 52-week range extends from a low of $90.39 to a high of $212.75.

INSM News

Simply Wall St 5h
How Raised Revenue Guidance Will Impact Insmed Investors

Insmed reported third quarter and nine month 2026 results that showed a smaller net loss and lower loss per share, while also raising full year revenue guidance...

How Raised Revenue Guidance Will Impact Insmed Investors
Simply Wall St 2d
Is Insmed Cheap After Strong Revenue And Higher 2026 Guidance?

Insmed (INSM) is back in focus after quarterly results showed stronger than expected revenue, driven by BRINSUPRI and ARIKAYCE. The company also reported higher...

Simply Wall St 3d
Insmed Stock Jumps After Q3 Earnings Fuel Growth And Loss Debate

Insmed stock ripped higher on Friday, jumping about 15% to US$111.59 after its third quarter 2026 report, as traders rushed to reprice the story. The move came...

Analyst ratings

96%

of 25 ratings
Buy
96%
Hold
4%
Sell
0%

People also own

Based on the portfolios of people who own INSM. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.